Big Picture – A Deep Dive Examination of SkinBioTherapeutics PLC
SkinBioTherapeutics PLC Snapshot
Martin has over 30 years' experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc. Martin is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board.
Dr Cath O'Neill
Chief Executive Officer
Cath is an accomplished biologist and a leader in human-bacterial interactions. Cath previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Cath has worked as an advisor for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto to new product concepts in partnership with global corporations. Cath is a biochemist by training and has previously led research teams as a senior lecturer at the University of Manchester.
Chief Financial Officer
Doug has spent the last 15 years involved in start-up and early stage businesses helping to manage them through subsequent levels of growth and secure the requisite funding. Doug has operational experience both within finance and across other business functions as well as considerable corporate finance experience, including in public markets. He was previously CFO at AIM listed Arthro Kinetics Plc and is currently CFO with regenerative medicine company Videregen and prior to joining Skin Biotherapeutics was CFO with University of Manchester spinout Gelexir Healthcare.
Stephen O'Hara spent 20 years working for the National Health Service (NHS) where he was responsible for delivering microbiology services to a large university teaching hospital. Stephen left the NHS in 2000 to set up an internet auction house, Acolyte Biomedica Limited (Acolyte), which developed rapid diagnostics for healthcare acquired infections such as MRSA. Acolyte was sold to 3M in 2007 where Stephen became Director of Microbiology. Stephen left 3M in 2009 to become a Director at Taunton and Somerset Foundation Trust. In 2011 he founded Intelligent Biotech Limited as a vehicle to identify technologies and market opportunities in healthcare, which has enabled him to identify the emerging potential of the human microbiome and set up OptiBiotix. During over 30 years in microbiology and healthcare, Stephen has authored over 40 articles, including chapters in several books, and is the inventor on a number of patents. He has at various times been editorial referee for the Journal of Medical Pathology and Journal of Clinical Microbiology.
Dr Cathy Prescott
Cathy has over two decades of experience in research, management and business in the biotechnology, pharmaceutical and venture capital sectors. Founder/Director of the consultancy Biolatris Ltd., non-executive Director Videregen Ltd., chair of the Trakcel Ltd Advisory Board, Translation Advisory Group member Babraham Institute and Member of the Board of Trustees IMET2000. She is also a visiting professor at Kings College (London) teaching on the MSc programme 'Cellular Therapies from bench to market' and Senior Associate for the Masters in Bioscience Enterprise (Cambridge University).
|Number||Ordinary Shares %|
|OptiBiotix Health Plc||49,794,190||41.9%|
|Seneca Partners Limited||17,388,889||14.6%|
|The University of Manchester||8,511,438||7.2%|
|Dr. Catherine O'Neill||5,256,989||4.4%|
|Professor Andrew McBain||5,201,434||4.4%|
|Number||Ordinary Shares %|
|Dr Catherine O'Neill||5,256,989||4.4%|
*Martin Hunt's shareholding is held through Invictus Management Limited, a company controlled by Mr Hunt. Of the 466,667 shares held by Invictus Management Limited 22,223 are held in trust for Louise Hunt and 22,222 are held in trust for Oliver Hunt.
15 Silk House
0161 468 2760